Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

IOVA – Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.
IOVA
$1.69
Name : Iovance Biotherapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $564,348,480.00
EPSttm : -1.22
finviz dynamic chart for IOVA
Iovance Biotherapeutics, Inc.
$1.69
2.87%
$0.05

Float Short %

33.51

Margin Of Safety %

Put/Call OI Ratio

0.14

EPS Next Q Diff

0.11

EPS Last/This Y

0.22

EPS This/Next Y

0.35

Price

1.71

Target Price

10.7

Analyst Recom

1.75

Performance Q

-53.44

Relative Volume

1.29

Beta

0.86

Ticker: IOVA




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02IOVA1.7550.100.10168448
2025-06-03IOVA1.8150.100.02169568
2025-06-04IOVA1.8350.100.06170717
2025-06-05IOVA1.7950.100.10171266
2025-06-06IOVA2.050.101.23171944
2025-06-09IOVA2.2050.130.64175006
2025-06-10IOVA2.380.160.05180978
2025-06-11IOVA2.230.150.05185224
2025-06-12IOVA2.310.150.20186636
2025-06-13IOVA2.240.160.03188243
2025-06-16IOVA2.080.160.63186733
2025-06-17IOVA2.020.160.88187344
2025-06-18IOVA2.040.170.71189144
2025-06-20IOVA1.960.170.36189876
2025-06-23IOVA1.850.160.03142618
2025-06-24IOVA1.870.150.01146747
2025-06-25IOVA1.770.150.01149676
2025-06-26IOVA1.7350.150.26151195
2025-06-27IOVA1.70.140.01152094
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02IOVA1.7520.8-19.6-1.06
2025-06-03IOVA1.8220.8-43.9-1.06
2025-06-04IOVA1.8420.8-21.4-1.06
2025-06-05IOVA1.8020.8-1.8-1.06
2025-06-06IOVA2.0520.8-132.4-1.06
2025-06-09IOVA2.2120.8-72.9-1.06
2025-06-10IOVA2.3820.8-68.4-1.06
2025-06-11IOVA2.2320.827.9-1.06
2025-06-12IOVA2.3120.8-37.0-1.06
2025-06-13IOVA2.2420.84.5-1.06
2025-06-16IOVA2.0720.837.9-1.06
2025-06-17IOVA2.0220.86.6-1.06
2025-06-18IOVA2.0420.8-22.2-1.06
2025-06-20IOVA1.9820.87.0-1.06
2025-06-23IOVA1.8520.834.6-1.06
2025-06-24IOVA1.8720.8-23.4-1.06
2025-06-25IOVA1.7720.832.6-1.06
2025-06-26IOVA1.7320.84.1-1.06
2025-06-27IOVA1.7120.81.9-1.06
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02IOVA0.05-0.6428.36
2025-06-03IOVA0.05-0.6428.36
2025-06-04IOVA0.05-0.6428.36
2025-06-05IOVA0.05-0.6428.36
2025-06-06IOVA0.10-0.6428.36
2025-06-09IOVA0.10-0.6428.36
2025-06-10IOVA0.10-0.6428.37
2025-06-11IOVA0.10-0.6431.81
2025-06-12IOVA0.10-0.6431.81
2025-06-13IOVA0.10-0.6431.81
2025-06-16IOVA0.10-0.6631.81
2025-06-17IOVA0.10-0.6631.81
2025-06-18IOVA0.10-0.6631.81
2025-06-20IOVA0.10-0.6631.81
2025-06-23IOVA0.10-0.6431.81
2025-06-24IOVA0.10-0.6431.81
2025-06-25IOVA0.10-0.6431.81
2025-06-26IOVA0.10-0.6433.51
2025-06-27IOVA0.10-0.6433.51
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.36

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

-0.25

Insider Transactions

0.1

Institutional Transactions

-0.64

Beta

0.86

Average Sales Estimate Current Quarter

67

Average Sales Estimate Next Quarter

78

Fair Value

Quality Score

27

Growth Score

32

Sentiment Score

1

Actual DrawDown %

96.9

Max Drawdown 5-Year %

-96.8

Target Price

10.7

P/E

Forward P/E

PEG

P/S

2.65

P/B

0.73

P/Free Cash Flow

EPS

-1.23

Average EPS Est. Cur. Y​

-1.06

EPS Next Y. (Est.)

-0.71

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-176.49

Relative Volume

1.29

Return on Equity vs Sector %

-72.8

Return on Equity vs Industry %

-54.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.28

EBIT Estimation

1.9
Iovance Biotherapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 838
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
stock quote shares IOVA – Iovance Biotherapeutics, Inc. Stock Price stock today
news today IOVA – Iovance Biotherapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch IOVA – Iovance Biotherapeutics, Inc. yahoo finance google finance
stock history IOVA – Iovance Biotherapeutics, Inc. invest stock market
stock prices IOVA premarket after hours
ticker IOVA fair value insiders trading